IP Verse

Use Of Il-33 Antagonists To Treat Fibrotic Disease - EP2475388

The patent EP2475388 was granted to Merck Sharp & Dohme on Nov 8, 2017. The application was originally filed on Sep 1, 2010 under application number EP10815921A. The patent is currently recorded with a legal status of "Opposition Rejected".

EP2475388

MERCK SHARP & DOHME
Application Number
EP10815921A
Filing Date
Sep 1, 2010
Status
Opposition Rejected
Mar 27, 2020
Publication Date
Nov 8, 2017
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

ELI LILLYAug 8, 2018KENTWITHDRAWN

Patent Citations (49) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONUS2006115453
DESCRIPTIONUS2008003199
DESCRIPTIONUS4816567
DESCRIPTIONUS5830761
DESCRIPTIONUS6506559
DESCRIPTIONUS6673611
DESCRIPTIONUS7071311
DESCRIPTIONUS7078196
DESCRIPTIONUS7560530
DESCRIPTIONWO0175164
DESCRIPTIONWO02096927
DESCRIPTIONWO03070742
DESCRIPTIONWO03070886
DESCRIPTIONWO03070888
DESCRIPTIONWO03070895
DESCRIPTIONWO03070914
DESCRIPTIONWO03070918
DESCRIPTIONWO03070966
DESCRIPTIONWO03070983
DESCRIPTIONWO03072590
DESCRIPTIONWO03072705
DESCRIPTIONWO03074654
DESCRIPTIONWO03078097
DESCRIPTIONWO2004013280
DESCRIPTIONWO2004013355
DESCRIPTIONWO2004014312
DESCRIPTIONWO2004058940
DESCRIPTIONWO2004093788
DESCRIPTIONWO2005003350
DESCRIPTIONWO2005019453
DESCRIPTIONWO2005044981
DESCRIPTIONWO2005045034
DESCRIPTIONWO2007140205
DESCRIPTIONWO2008144610
DESCRIPTIONWO9003430
DESCRIPTIONWO9932619
DESCRIPTIONWO9954459
INTERNATIONAL-SEARCH-REPORTUS2007160579
INTERNATIONAL-SEARCH-REPORTUS2008003199
INTERNATIONAL-SEARCH-REPORTUS7560530
INTERNATIONAL-SEARCH-REPORTWO2007140205
INTERNATIONAL-SEARCH-REPORTWO2008144610
OPPOSITIONUS2005203046
OPPOSITIONUS2007160579
OPPOSITIONWO2007140205
OPPOSITIONWO2008132709
OPPOSITIONWO2008144610
SEARCHWO2008022761
SEARCHWO2008132709

Non-Patent Literature (NPL) Citations (100) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
DESCRIPTION- ALIPRANTIS ET AL., PROC. NAT'L ACAD. SCI. (USA), (2007), vol. 104, pages 2827 - 2830
DESCRIPTION- AMATUCCI ET AL., J. LEUKOCYTE BIOL., (2007), vol. 82, page 124
DESCRIPTION- AMERSHAM PHARMACIA BIOTECH, BioDirectory, (2001), pages 384 - 391
DESCRIPTION- AUSBEL ET AL., Current Protocols in Molecular Biology, JOHN WILEY AND SONS, INC., (2001), vol. 1-4
DESCRIPTION- AUSUBEL ET AL., Current Protocols in Molecular Biology, JOHN WILEY AND SONS, INC., (2001), vol. 3
DESCRIPTION- BAEKKEVOLD ET AL., AM. J. PATHOL., (2003), vol. 163, pages 69 - 79
DESCRIPTION- CARRIERE ET AL., PROC. NAT'L ACAD. SCI. (USA), (2007), vol. 104, pages 282 - 287
DESCRIPTION- CAYROL; GIRARD, PROC. NAT'L ACAD. SCI. (USA), (2009), vol. 106, pages 9021 - 9026
DESCRIPTION- CHACKERIAN ET AL., J IMMUNOL, (2007), vol. 179, pages 2551 - 2555
DESCRIPTION- CHERRY ET AL., J. ALLERGY CLIN. IMMUNOL., (2008), vol. 121, pages 1484 - 1490
DESCRIPTION- CHIARAMONTE ET AL., J. CLIN. INVEST., (1999), vol. 104, pages 777 - 785
DESCRIPTION- CLACKSON ET AL., NATURE, (1991), vol. 352, pages 624 - 628
DESCRIPTION- COLIGAN ET AL., Current Protocols in Immunology, JOHN WILEY AND SONS, INC., (2001), vol. 1
DESCRIPTION- COLIGAN ET AL., Current Protocols in Immunology, JOHN WILEY, INC., (2001), vol. 4
DESCRIPTION- COLIGAN ET AL., Current Protocols in Protein Science, JOHN WILEY AND SONS, INC., (2000), vol. 1
DESCRIPTION- COLIGAN ET AL., Current Protocols in Protein Science, JOHN WILEY AND SONS, INC., (2000), vol. 2
DESCRIPTION- CULLINAN, J. IMMUNOL., (1998), vol. 161, pages 5614 - 5620
DESCRIPTION- FIRE ET AL., NATURE, (1998), vol. 391, page 806
DESCRIPTION- FRIEDMAN, GASTROENTEROLOGY, (2008), vol. 134, pages 1655 - 1669
DESCRIPTION- GABRIELLI ET AL., CURR. OP. IMMUNOL., (2007), vol. 19, page 640
DESCRIPTION- GLACCUM ET AL., J. IMMUNOL., (1997), vol. 159, pages 3364 - 3371
DESCRIPTION- HARALDSEN ET AL., TRENDS IMMUNOL., (2009), vol. 30, pages 227 - 233
DESCRIPTION- HOSHINO ET AL., J. EXP. MED., (1999), vol. 190, pages 1541 - 1547
DESCRIPTION- HUSE ET AL., SCIENCE, (1989), vol. 246, page 1275
DESCRIPTION- HUSE ET AL., SCIENCE, (1989), vol. 246, pages 1275 - 1281
DESCRIPTION- J. IMMUNOL., (2004), vol. 173, pages 3425 - 3431
DESCRIPTION- J IMMUNOL, (2007), vol. 179, pages 2551 - 2555
DESCRIPTION- KOHLER ET AL., NATURE, (1975), vol. 256, page 495
DESCRIPTION- KOHLER; MILSTEIN, EUR. J. IMMUNOL., (1976), vol. 6, pages 511 - 519
DESCRIPTION- KOLODSICK ET AL., J. IMMUNOL., (2004), vol. 172, pages 4068 - 4076
DESCRIPTION- KONDO ET AL., INTERNATIONAL IMMUNOLOGY, (2008), vol. 20, pages 791 - 800
DESCRIPTION- KONDO ET AL., INT. IMMUNOL., (2008), vol. 20, pages 791 - 800
DESCRIPTION- KUCHLER ET AL., AM. J. PATHOL., (2008), vol. 173, pages 1229 - 1242
DESCRIPTION- KUROIWA ET AL., BIOCHEM. BIOPHYS. RES. COMM., (2001), vol. 284, pages 1104 - 1108
DESCRIPTION- LAMBERT ET AL., CRIT. REV. ONCOL. HEMATOL., (2004), vol. 49, pages 187 - 198
DESCRIPTION- LEONARDI ET AL., INVEST. OPHTHALMOL. & VISUAL SCI., (2003), vol. 44, pages 183 - 189
DESCRIPTION- LEUNG ET AL., J. IMMUNOL., (2004), vol. 173, pages 145 - 150
DESCRIPTION- LOHNING ET AL., PROC. NAT'L ACAD. SCI. (USA), (1998), vol. 95, pages 6930 - 6935
DESCRIPTION- LUTHI ET AL., IMMUNITY, (2009), vol. 31, page 84
DESCRIPTION- MARKS ET AL., J. MOL. BIOL., (1991), vol. 222, pages 581 - 597
DESCRIPTION- MARVIE ET AL., J. CELL. MOL. MED., (2010), vol. 14, no. 6B, page 1726
DESCRIPTION- MCKENZIE ET AL., CURR. BIOL., (1998), vol. 8, pages 339 - 342
DESCRIPTION- MELTZER; NOBLE, ORPHANET J. RARE DIS., (2008), vol. 3, page 8
DESCRIPTION- MENDEZ ET AL., NATURE GENETICS, (1997), vol. 15, pages 146 - 156
DESCRIPTION- METWALI ET AL., J. IMMUNOL., (1996), vol. 157, pages 4546 - 4553
DESCRIPTION- MOMBAERTS ET AL., CELL, (1992), vol. 68, pages 869 - 877
DESCRIPTION- MORRISON ET AL., PROC. NATL. ACAD. SCI. USA, (1984), vol. 81, pages 6851 - 6855
DESCRIPTION- MOUSSION ET AL., PLOS ONE, (2008), vol. 3, page E3331
DESCRIPTION- PADDISON ET AL., PROC. NAT'L. ACAD. SCI. (USA, (2002), vol. 99, page 1443
DESCRIPTION- QUEEN ET AL., PROC. NAT'L ACAD. SCI. USA, (1989), vol. 86, pages 10029 - 10033
DESCRIPTION- RANKIN ET AL., J. IMMUNOL., (2010), vol. 184, page 1526
DESCRIPTION- SAH, LIFE SCI., (2006), vol. 79, page 1773
DESCRIPTION- SANADA ET AL., J. CLIN. INVEST., (2007), vol. 117, pages 1538 - 1549
DESCRIPTION- SCHMITZ ET AL., IMMUNITY, (2005), vol. 23, pages 479 - 490
DESCRIPTION- SELMAN; PARDO, PROC. AM. THORAC. SOC., (2006), vol. 3, pages 364 - 372
DESCRIPTION- SHIMIZU ET AL., HUM. MOL. GENET., (2005), vol. 14, pages 2919 - 2927
DESCRIPTION- SIGMA-ALDRICH, CO., Products for Life Science Research, (2001), pages 45 - 89
DESCRIPTION- SIVAKUMAR; DAS, INFLAMM. RES., (2008), vol. 57, pages 410 - 418
DESCRIPTION- SMITHGALL, INT. IMMUNOL., (2008), vol. 20, pages 1019 - 1030
DESCRIPTION- STITES ET AL., BASIC AND CLINICAL IMMUNOLOGY (4th ed.), LANGE MEDICAL PUBLICATIONS
DESCRIPTION- SUZUKAWA ET AL., LAB. INVEST, (2008), vol. 88, pages 1245 - 1253
DESCRIPTION- SYED ET AL., RESP. RES., (2005), vol. 6, page 9
DESCRIPTION- TAJIMA ET AL., CHEST, (2003), vol. 124, pages 1206 - 1214
DESCRIPTION- TROJANOWSKA; VARGA, CURR. OPIN. RHEUMATOL., (2007), vol. 19, pages 568 - 573
DESCRIPTION- WARD ET AL., NATURE, (1989), vol. 341, page 544
DESCRIPTION- WU, Recombinant DNA, ACADEMIC PRESS, (1993), vol. 217
DESCRIPTION- WYNN, J. PATHOL., (2008), vol. 214, pages 199 - 210
DESCRIPTION- YU ET AL., J. EXP. MED., (2002), vol. 195, pages 1387 - 1395
DESCRIPTION- ZENDER ET AL., PROC. NAT'L. ACAD. SCI. (USA), (2003), vol. 100, page 7797
DESCRIPTION- ZHENG ET AL., J. INVEST. DERMATOL., (2009), vol. 129, pages 742 - 751
DESCRIPTION- ZHOU ET AL., J. CLIN. INVEST., (1999), vol. 103, pages 779 - 788
INTERNATIONAL-SEARCH-REPORT- SANADA ET AL., "IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system.", J. CLIN. INVEST., (200706), vol. 117, no. 6, pages 1538 - 1549, XP008152558
INTERNATIONAL-SEARCH-REPORT- MOUSSION ET AL., "The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel 'alarmin'?", PLOS ONE., (20081006), vol. 3, no. 10, pages 1 - 8, XP055016644
INTERNATIONAL-SEARCH-REPORT- CHACKERIAN ET AL., "IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex.", J. IMMUNOL., (20070815), vol. 178, no. 4, pages 2551 - 2555, XP008152567
OPPOSITION- GUPTA, "Localized scleroderma and systemic sclerosis: Is there a connection?", Best Practice & Res Clin Rheum, (20070000), vol. 21, no. 6, pages 1025 - 1036, XP022372339
OPPOSITION- "interleukin 33 isoform a precursor [Homo sapien]", Protein, (20180805), Database accession no. NM_254274, XP055621146
OPPOSITION- OLIVER, "The Th1/Th2 Paradigm in the Pathogenesis of Scleroderma, and Its Modulation by Thalidomide", Current Rheumatology Reports, (20000000), vol. 2, pages 486 - 491, XP007913640
OPPOSITION- WYNN, "Cellular and molecular mechanisms of fibrosis", J Pathol, (20080000), vol. 214, pages 199 - 210, XP002553819
OPPOSITION- LIU et al., "Anti-IL-33 antibody treatment inhibits airway inflammation in a murine model of allergic asthma", Biochem and biophys Res Comm, (20090000), vol. 386, pages 181 - 185, XP026237394
OPPOSITION- GABRIELLI et al., "Pathogenic autoantibodies in systemic sclerosis", Current Opinion in Immunology, (20070000), vol. 19, pages 640 - 645, XP022388466
OPPOSITION- SCHMITZ et al., "IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines", Immunity, (20051100), vol. 23, pages 479 - 490, XP002432892
OPPOSITION- ABRAHAM et al., "Scleroderma: from cell and molecular mechanisms to disease models", Trends in Immunology, (20051100), vol. 26, no. 11, pages 587 - 595, XP005146750
OPPOSITION- PHILLIP J. STONE, "Potential use of collagen and elastin degradation markers for monitoring liver fibrosis in schistosomiasis", Acta Tropica, (20000000), vol. 77, pages 97 - 99, XP002601194
OPPOSITION- KAKKAR et al., "The IL-33/ST2 pathway: Therapeutic target and novel biomarker", Nature Reviews, (20081000), vol. 7, pages 827 - 840, XP002530680
OPPOSITION- WYNN, "FIBROTIC DISEASE AND THE TH1/TH2 PARADIGM", Nature Reviews , Immunology, (20040800), vol. 4, pages 583 - 594, XP009070836
OPPOSITION- MARVIE et al., "Interleukin-33 overexpression is associated with liver fibrosis in mice and humans", J. Cell . Mol. Med., (20090605), vol. 14, no. 6B, pages 1726 - 1739, XP009167820
OPPOSITION- MANETTI et al., "The IL1-like cytokine IL33 and its receptor ST2 are abnormally expressed in the affected skin and visceral organs of patients with systemic sclerosis", Ann Rheum Dis, (20090923), vol. 69, pages 598 - 605, XP009167830
OPPOSITION- MILLER, "Role of IL-33 in inflammation and disease", Journ. Of Inflammation, (20110000), vol. 8, no. 22, pages 1 - 12, XP021109127
OPPOSITION- RANKIN et al., "IL-33 Induces IL-13-Dependent Cutaneous Fibrosis", J.Immunol, (20091230), vol. 184, pages 1526 - 1535, XP009167831
SEARCH- KASAIAN M T ET AL, "IL-13 as a therapeutic target for respiratory disease", BIOCHEMICAL PHARMACOLOGY, PERGAMON, OXFORD, GB, vol. 76, no. 2, ISSN 0006-2952, (20080715), pages 147 - 155, (20080416), XP026960884 [Y] 1-13 * the whole document * * page 149, column l, paragraph 4. *
SEARCH- PFLANZ STEFAN ET AL, "II-33 induces II-13-dependent cutaneous fibrosis", INFLAMMATION RESEARCH, & 8TH WORLD CONGRESS ON TRAUMA, SHOCK, INFLAMMATION AND SEPSIS/23RD SIS-EUROPE CONGRESS ON SURGICAL IN; MUNICH, GERMANY; MARCH 09 -13, 2010, (2010), vol. 59, no. Suppl. 1, ISSN 1023-3830, page S109, XP009167834 [IP] 1-13 * the whole document *
SEARCH- SANADA SHOJI ET AL, "IL-33/ST2 is a critical cardioprotective fibroblast-cardiomyocyte signaling system activated by mechanical overload", CIRCULATION, LIPPINCOTT WILLIAMS & WILKINS, US, (20061001), vol. 114, no. 18, Suppl, ISSN 0009-7322, page 263, XP009167836 [Y] 1-13 * the whole document *
SEARCH- LIU X ET AL, "Anti-IL-33 antibody treatment inhibits airway inflammation in a murine model of allergic asthma", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 386, no. 1, doi:10.1016/J.BBRC.2009.06.008, ISSN 0006-291X, (20090814), pages 181 - 185, (20090607), XP026467441 [Y] 1-13 * the whole document *
SEARCH- SCHMITZ J ET AL, "IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines", IMMUNITY, CELL PRESS, US, (20051101), vol. 23, no. 5, doi:10.1016/J.IMMUNI.2005.09.015, ISSN 1074-7613, pages 479 - 490, XP002432892 [Y] 1-13 * the whole document * * abstract * * page 483, column r, paragraph l - page 484, column r, paragraph l * * Discussion *
SEARCH- KAKKAR R ET AL, "The IL-33/ST2 pathway: Therapeutic target and novel biomarker", NATURE REVIEWS. DRUG DISCOVERY, NATURE PUBLISHING GROUP, GB, (20080101), vol. 7, no. 10, doi:10.1038/NRD2660, ISSN 1474-1784, pages 827 - 840, XP002530680 [Y] 1-13 * page 832, column 3, paragraph 2 *
SEARCH- H. HAYAKAWA ET AL, "Soluble ST2 Blocks Interleukin-33 Signaling in Allergic Airway Inflammation", JOURNAL OF BIOLOGICAL CHEMISTRY, (20070101), vol. 282, no. 36, doi:10.1074/jbc.M704916200, ISSN 0021-9258, pages 26369 - 26380, XP055030354 [Y] 1-13 * the whole document * * abstract * * page 26372, column r, paragraph l - page 26373, column r, paragraph 1 * * page 26379, column l, paragraphs 2, l *
SEARCH- TAJIMA SHUNJI ET AL, "ST2 gene induced by type 2 helper T cell (Th2) and proinflammatory cytokine stimuli may modulate lung injury and fibrosis.", EXPERIMENTAL LUNG RESEARCH MAR 2007, (200703), vol. 33, no. 2, ISSN 0190-2148, pages 81 - 97, XP009167841 [Y] 1-13 * the whole document * * page 83, paragraph l - page 84, paragraph 1 * * page 92, paragraph 2 * * page 94 *
SEARCH- KONDO YUICHI ET AL, "Administration of IL-33 induces airway hyperresponsiveness and goblet cell hyperplasia in the lungs in the absence of adaptive immune system", INTERNATIONAL IMMUNOLOGY, OXFORD UNIVERSITY PRESS, GB, (20080601), vol. 20, no. 6, doi:10.1093/INTIMM/DXN037, ISSN 0953-8178, pages 791 - 800, XP009167832 [Y] 1-13 * the whole document * * page 792, column l, paragraph 3 * * Discussion *
SEARCH- MARVIE PIERRICK ET AL, "Interleukin-33 overexpression is associated with liver fibrosis in mice and humans.", JOURNAL OF CELLULAR AND MOLECULAR MEDICINE JUN 2010, (20090605), vol. 14, no. 6B, ISSN 1582-4934, pages 1726 - 1739, XP009167820 [Y] 1-13 * the whole document *
SEARCH- RANKIN ANDREW L ET AL, "IL-33 Induces IL-13-Dependent Cutaneous Fibrosis", JOURNAL OF IMMUNOLOGY, (201002), vol. 184, no. 3, ISSN 0022-1767, pages 1526 - 1535, XP009167831 [IP] 1-13 * the whole document *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents